Brand-name drug
Premarin price, strengths & recalls
Brand of estrogens, conjugated (usp) (generic)
Pharmacies pay $208.17 for 30 tablets of Premarin 0.625 mg tablet this week, and from $208.02 to $452.22 across its 6 priced strengths and forms. The generic, estrogens, conjugated (usp), costs pharmacies from $158.91. It has 1 recall on record, none ongoing. Its official label last changed on June 3, 2026.
Brand- Fair cash price
- $249.90
- Strengths
- 6
- Makers
- 1
- Updated
- Nov 11
Premarin price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.3 mg tablet Brand | $6.95 | $208.46 / 30 tablets |
| 0.45 mg tablet Brand | $6.95 | $208.56 / 30 tablets |
| 0.625 mg tablet Brand | $6.94 | $208.17 / 30 tablets |
| 0.9 mg tablet Brand | $6.93 | $208.02 / 30 tablets |
| 1.25 mg tablet Brand | $6.95 | $208.44 / 30 tablets |
| 0.625 mg/mL vaginal cream Brand | $15.07 | $452.22 / 30 g |
The lowest cost per tablet is 0.9 mg tablet at $6.93. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Premarin vs generic estrogens, conjugated (usp)
Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:
| Strength | Brand | Generic | Brand costs |
|---|---|---|---|
| 0.3 mg tablet | $208.46 | $158.91 | 1.3x |
| 0.45 mg tablet | $208.56 | $160.44 | 1.3x |
| 0.625 mg tablet | $208.17 | $161.34 | 1.3x |
| 0.9 mg tablet | $208.02 | $167.04 | 1.2x |
| 1.25 mg tablet | $208.44 | $164.19 | 1.3x |
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Premarin
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use PREMARIN safely and effectively. See full prescribing information for PREMARIN. PREMARIN® (conjugated estrogens) tablets, for oral use Initial U.S. Approval: 1942
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA
See full prescribing information for complete boxed warning.
Estrogen-Alone Therapy
•
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (5.2)
•
Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3)
•
Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) (5.1)
•
The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)
Estrogen Plus Progestin Therapy
•
Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3)
•
The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI) (5.1)
•
The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (5.2)
•
The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)
Estrogen-Alone Therapy
Endometrial Cancer
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2)].
Cardiovascular Disorders and Probable Dementia
Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.5, 14.6)].
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) (0.625 mg)-alone, relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.5)].
The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.6)].
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Estrogen Plus Progestin Therapy
Cardiovascular Disorders and Probable Dementia
Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.5, 14.6)].
The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.5)].
The WHIMS estrogen plus progestin ancillary study of the WHI, reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.6)].
Breast Cancer
The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2), and Clinical Studies (14.5)].
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins.
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA004782 · Wyeth Pharms
- First approved
- May 8, 1942 (84 years ago)
- Latest approved change
- April 22, 2025
- Approved label
- PDF, Apr 25, 2025
- Generic makers
- 2 approved generic applications on the market
Premarin questions
How much does premarin cost without insurance?
Pharmacies pay about $208.17 for 30 tablets of premarin 0.625 mg tablet ($6.94 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $249.90. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Premarin?
Yes: estrogens, conjugated (usp). Pharmacies pay from $158.91 for it. Compare estrogens, conjugated (usp) prices.
Is premarin in shortage?
No shortage is reported for premarin right now. We check the national shortage list every day.
Has premarin been recalled?
1 recall on record, none ongoing. Recalls name specific lots - check yours.
When did the premarin label last change?
The official label was last updated on June 3, 2026 (version 37). See what changed.
Talk about premarin
No comments yet. Questions, tips, what worked for you - start the conversation.